FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast CancerPRNewsWire • Friday
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from StakeholdersPRNewsWire • 10/29/24
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation SystemPRNewsWire • 10/21/24
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging ConferencePRNewsWire • 10/07/24
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free RatePRNewsWire • 09/24/24
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft TissuesPRNewsWire • 09/16/24
IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024PRNewsWire • 09/12/24
IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets ConferencesPRNewsWire • 09/04/24
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation TechnologiesPRNewsWire • 08/28/24
IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/20/24
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global MarketsPRNewsWire • 08/20/24
IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of SurgeryPRNewsWire • 08/14/24
IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024PRNewsWire • 08/13/24
IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"PRNewsWire • 08/07/24
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer SocietyPRNewsWire • 07/22/24
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast CancerPRNewsWire • 07/09/24
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbesPRNewsWire • 07/01/24
IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024PRNewsWire • 06/18/24
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal FunctionPRNewsWire • 06/12/24
IceCure Medical (ICCM) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 06/04/24
FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness PlanPRNewsWire • 06/04/24
